Synopsis The objective of present study was to evaluate the treatment effects of the IL-6R antibody tocilizumab and cyclophosphamide (CTX) in patients with Takayasu arteritis (TA) and explore the mechanism by analyzing their effects on various cytokines. This week’s “MED FACT” discusses a clinical trial from International Journal of Cardiology, “Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide”. Authors: XiufangKong et.al.
Key Takeaways: The IL-6R antibody may be more effective in mitigating vascular inflammation and remodeling than CTX. Objective: To compare treatment effect of Tocilizumab and cyclophosphamide Study Type: Randomized trial Participants: 48 What Was The Need For This Study? Tocilizumab and cyclophosphamide can improve patients’ manifestations and spare glucocorticoids usage without adverse effect in Takayasu Arteritis. What Was The…
